Efficacy of carbapenems against a metallo-β-lactamase-producing Escherichia coli clinical isolate in a rabbit intra-abdominal abscess model

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 3, 2011, Pages 611-617

  Souli, Maria ^a   Konstantinidou, Eleftheria ^b   Tzepi, Ira ^a   Tsaganos, Thomas ^a   Pefanis, Angelos ^a,c   Chryssouli, Zoi ^a   Galani, Irene ^a   Giamarellos Bourboulis, Evangelos ^a   Giamarellou, Helen ^a,d  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c Hospital for Diseases of the Chest 'SOTIRIA'   (Greece)

^d HYGEIA HOSPITAL   (Greece)

Author keywords

Aztreonam; Ertapenem; Imipenem; Meropenem; VIM

Indexed keywords

AMIKACIN; AZTREONAM; CARBAPENEM; CEFEPIME; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; TOBRAMYCIN;

ABDOMINAL ABSCESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; ENZYME SYNTHESIS; ESCHERICHIA COLI; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; RABBIT;

ABDOMINAL ABSCESS; ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARBAPENEMS; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; MALE; RABBITS; RODENT DISEASES; TREATMENT OUTCOME;

EID: 79951544289     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq470     Document Type: Article

References (22)

1. Cornaglia G, Akova M, Amicosante G et al. Metallo-β-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int J Antimicrob Agents 2007; 29: 380-8.
2. Souli M, Kontopidou FV, Papadomichelakis E et al. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-β-lactamase in a Greek university hospital. Clin Infect Dis 2008; 46: 847-54.
3. Daikos GL, Petrikkos P, Psichogiou M et al. Prospective observational study of the impact of VIM-1 metallo-β-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009; 53: 1868-73.
4. Miriagou V, Cornaglia G, Edelstein M et al. Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect 2010; 16: 112-22.
5. VIM-1. J Antimicrob Chemother 2006; 58: 669-72.
6. Carmeli Y, Akova M, Cornaglia G et al. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin Microbiol Infect 2010; 16: 102-11.
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement M100-S18. CLSI, Wayne, PA, USA, 2008.
8. Lee K, Chong Y, Shin HB et al. Modified Hodge and EDTA-disk synergy tests to screen metallo-β-lactamase-producing strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect 2000; 7: 88-91.
9. Poirel L, Naas T, Nicolas D et al. Characterization of VIM-2, a carbapenemhydrolysing metallo-β-lactamase and its plasmid-and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother 2000; 44: 891-7.
10. Sabath LD, Anhalt JP. Assay of antimicrobials. In: Lennette EH, Balows A, Hausler Jr et al., eds. Manual of Clinical Microbiology. Washington, DC: American Society for Microbiology, 1980; 485-90.
11. Tsaganos T, Kouki P, Digenis P et al. Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis. Int J Infect Dis 2008; 32: 46-9.
12. Schulin T, Thauvin-Eliopoulos C, Moellering RC et al. Activities of the oxazolidinones linezolid and eperezolid in experimental inta-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1999; 43: 2873-6.
13. Sakka SG, Glauner AK, Bulitta JB et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007; 51: 3304-10.
14. Thalhammer F, Traunmüller F, El Menyawi I et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999; 43: 523-7.
15. Nix DE, Majumdar AK, DiNubile MJ. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J Antimicrob Chemother 2004; 53 Suppl 2: ii23-8.
16. Vinks AA, van Rossem RN, Mathôt RAA et al. Parmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using Monte Carlo simulation. Antimicrob Agents Chemother 2007; 51: 3049-55.
17. Vatopoulos A. High rates of metallo-β-lactamase-producing Klebsiella pneumoniae in Greece - a review of the current evidence. Euro Surveill 2008; 13: pii=8023.
18. Galani I, Xirouchaki E, Kanellakopoulou K et al. Transferable plasmid mediating resistance to multiple antimicrobial agents in Klebsiella pneumoniae isolates in Greece. Clin Microbiol Infect 2002; 8: 579-88.
19. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2000; 36 Suppl 2: 42-50.
20. Daikos GL, Panagiotakopoulou A, Tzelepi E et al. Activity of imipenem against VIM-1 metallo-β-lactamase-producing Klebsiella pneumoniae in the murine thigh infection model. Clin Microbiol Infect 2007; 13: 202-5.
21. Galani I, Souli M, Koratzanis E et al. Emerging bacterial pathogens: Escherichia coli, Enterobacter aerogenes and Proteus mirabilis clinical isolates harbouring the same transferable plasmid coding for metallo-β-lactamase VIM-1 in Greece. J Antimicrob Chemother 2007; 59: 578-9.
22. VIM-1 and aac(6′)-IIc in an Enterobacter cloacae clinical isolate from Greece. J Antimicrob Chemother 2005; 55: 634-8.